Final Appraisal Recommendation

Advice No: 0318 – Feb 2018

Lacosamide (Vimpat®) 50 mg, 100 mg, 150 mg, 200 mg film-coated tablets; 10 mg/ml syrup; 10 mg/ml solution for infusion

Limited submission by UCB Pharma Ltd.

Recommendation of AWMSG

Lacosamide (Vimpat®) is recommended as an option for use within NHS Wales as adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalisation in children from ≥ 4 years of age to ≤ 15 years of age with epilepsy.

Additional note(s):

- Please refer to the Summary of Product Characteristics for the full licensed indication.

In reaching the above recommendation AWMSG has taken account of the appraisal documentation prepared by the AWMSG Secretariat (reference number 3343), which includes the AWMSG Secretariat Assessment Report (ASAR), the Preliminary Appraisal Recommendation (PAR) and the applicant company's response to the PAR, clinical expert opinion (where available), the views of patients/patient carers (where available) and the lay member perspective.

This recommendation has been ratified by Welsh Government and will be considered for review every three years.

Marketing authorisation holder on first issue	UCB Pharma Ltd
Date of first issue	February 2018
Last reviewed	March 2021